This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Minniti, C. P. Articles by Helman, L. J. Search for Related Content PubMed PubMed Citation Articles by Minniti, C. P. Articles by Helman, L. J.

Suramin Inhibits the Growth of Human Rhabdomyosarcoma by Interrupting the Insulin-like Growth Factor II Autocrine Growth Loop

Molecular Genetics Section, Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892

Suramin is a polysulfonated naphthylurea with antineoplastic activity that binds various peptide growth factors. Since we previously demonstrated that insulin-like growth factor II (IGF-II) is an autocrine growth factor in human rhabdomyosarcoma (RMS), we studied the effect of suramin on the growth of human RMS cells. Suramin caused a dose-dependent decrease of RMS cell number grown either in 10% fetal bovine serum or in serum-free medium (half-maximal effective dose in mitogenic assays, 1.6 x 10^–4 and 9 x 10^–5 M, respectively). IGF-II and IGF-I added to RMS cells in the presence of suramin reversed the suramin-induced inhibition of cell growth. Since IGF-II exerts its mitogenic effects on RMS cells by binding to the type I receptor, we performed radioreceptor assays using ¹²⁵I-IGF-I and found that suramin displaced ¹²⁵I-IGF-I from the type I IGF receptor. There was an excellent correlation between the doses of suramin effective in inhibiting the growth of RMS cells and those that displaced the binding of IGF-I. Our data indicate that suramin exerts its effect on RMS cell growth by interfering with the binding of IGF-II to the type I IGF receptor, thereby interrupting the IGF-II autocrine growth in these cells. Disrupting autonomous growth of RMS may be a promising novel therapeutic approach.

¹ To whom requests for reprints should be addressed, at Molecular Genetics Section, Pediatric Branch, National Cancer Institute, Building 10, Room 13N240, Bethesda, MD 20892.

Received 8/28/91. Accepted 1/24/92.

This article has been cited by other articles:

				M. A. Villalona-Calero, M. G. Wientjes, G. A. Otterson, S. Kanter, D. Young, A. J. Murgo, B. Fischer, C. DeHoff, D. Chen, T.-K. Yeh, et al. Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3303 - 3311. [Abstract] [Full Text] [PDF]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				M. Nagamani and C. A. Stuart Specific Receptors and Growth Effects of Insulin and Insulin-Like Growth Factors in a Human Cell Line Derived From Mixed Mesodermal Tumor of the Uterus Reproductive Sciences, September 1, 1996; 3(5): 281 - 288. [Abstract] [PDF]